Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program
about
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2018
@uk
ലേഖനം
@ml
name
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@en
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@nl
type
label
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@en
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@nl
prefLabel
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@en
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@nl
P50
P356
P1476
Siltuximab in relapsed/refract ...... nce of the Italian NPP program
@en
P2093
Giacomo Malipiero
Lorenzo Tonialini
P304
P356
10.1002/HON.2532
P407
P577
2018-08-03T00:00:00Z